Copyright
©The Author(s) 2015.
World J Anesthesiol. Jul 27, 2015; 4(2): 17-29
Published online Jul 27, 2015. doi: 10.5313/wja.v4.i2.17
Published online Jul 27, 2015. doi: 10.5313/wja.v4.i2.17
Table 1 Immuno-modulating and anti-inflammatory effects of lignocaine
| Effects | Immuno-modulating and inflammatory actions |
| Anti-nociceptive and analgesic effects[12,16,17,34,101] | Interaction with nociceptive pathways |
| Blockade of neuronal sodium channels | |
| Blockade of potassium currents | |
| Muscarinic receptor antagonist | |
| Blockade of dopamine receptors | |
| Glycine inhibitor | |
| Reduction in excitatory amino acids | |
| Reduction in thromboxane | |
| Release of endogenous opioid peptides | |
| Reduction in neurokinins | |
| Release of ATP-adenosine triphosphate | |
| Wound healing effects[19,38,39,102-104] | Retardation by reduction of mucopolysaccharide and collagen synthesis |
| Reduction in recruitment and metabolic response of | |
| Inhibition of thrombus formation | |
| Antithrombotic activity | |
| Inhibition of platelet aggregation via blockade of calcium influx | |
| Mobilization of intracellular calcium stores | |
| Inhibition of oxygen free radical production | |
| Inhibition of inflammatory cytokines | |
| Inhibition of vascular permeability | |
| Inhibition of edema formation | |
| Inhibition of immune cell mediators from monocytes[18,105] | Inhibition of interleukin 1α |
| Inhibition of interleukin β | |
| Inhibition of interleukin 8 | |
| Inhibition of tumor necrosis factor | |
| Inhibition of immune cell mediators from neutrophils[18,24-26,28,33,102,106] | Inhibition of prostaglandins |
| Inhibition of thromboxanes | |
| Inhibition of leukotrienes | |
| Inhibition of lysosomal enzymes | |
| Inhibition of free radicals | |
| Inhibition of immune cell mediators from mast cells[36] | Inhibition of histamine release |
| Anti-bactericidal effects[16-18,43-46,107] | Inhibitory actions on Pseudomonas aeruginosa |
| Inhibitory actions on Escherichia coli | |
| Inhibitory actions on Staphylococcus aureus | |
| Inhibitory actions on Haemophilus influenza | |
| Inhibitory actions on Mycobacterium tuberculosis | |
| Anti-viral and anti-fungal effects[16,17,108] | Inhibitory actions on Herpes simplex virus |
| Inhibitory actions on Candida albicans | |
| Clinical effects in inflammation-related disease[109-117] | Protective effects in acute lung injury |
| Protective effects in septic shock | |
| Protective effects in cardiac ischemia | |
| Beneficial effects in ischemia-reperfusion injuries | |
| Protective effects in interstitial cystitis | |
| Protective effects in ulcerative colitis | |
| Protective effects in ulcerative proctitis | |
| Protective effects in burn injuries | |
| Accelerated return of bowel function in major surgery | |
| Blockade of airway hyperactivity in asthma | |
| Treatment of intractable hiccups | |
| Beneficial effects in traumatic brain injury |
Table 2 Adverse effects of lignocaine toxicity
| System | Effects |
| CNS | Biphasic effects |
| Early: CNS excitation with seizures | |
| Late: CNS depression, termination of convulsions, reduced level of consciousness, leading to respiratory depression and/or arrest | |
| Mechanism: Local inhibition of inhibitory CNS pathways (CNS stimulation), then inhibition of inhibitory and excitatory pathways (CNS inhibition) | |
| Symptoms and signs | |
| Anxiety | |
| Dizziness or light headed | |
| Confusion | |
| Euphoria | |
| Tinnitus | |
| Blurring of vision or diplopia | |
| Nausea and vomiting | |
| Twitching and tremors | |
| Seizures with reduced consciousness | |
| Cardiovascular | General effects |
| Conduction block of neural impulses | |
| Prevention of passage of sodium through sodium channels | |
| Stabilization of excitable membranes | |
| Prevention of the initiation and transmission of nerve impulses | |
| Attenuation of phase 4 diastolic depolarization | |
| Reduction in automaticity | |
| Reduction in absolute refractory period | |
| Increase in the ratio of effective refractory period: action potential duration | |
| Decrease in action potential duration | |
| Ventricular fibrillation threshold: raised | |
| Higher serum concentrations | |
| Blockage of sodium channels | |
| Depression of rate of depolarization during phase 0 of the cardiac action potential | |
| Re-entrant arrhythmias | |
| Suppression of conduction through the sinus and atrioventricular nodes | |
| Symptoms and signs | |
| Bradycardia | |
| Hypotension | |
| Cardiovascular depression | |
| Cardiac arrest | |
| Respiratory | Symptoms and signs |
| Tachypnea | |
| Respiratory depression | |
| Respiratory arrest | |
| Allergic reactions | Extremely rare |
| Symptoms and signs | |
| Cutaneous lesions: urticaria, edema | |
| Anaphylaxis |
- Citation: Weinberg L, Peake B, Tan C, Nikfarjam M. Pharmacokinetics and pharmacodynamics of lignocaine: A review. World J Anesthesiol 2015; 4(2): 17-29
- URL: https://www.wjgnet.com/2218-6182/full/v4/i2/17.htm
- DOI: https://dx.doi.org/10.5313/wja.v4.i2.17
